CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Minocycline +2 moredrug
Likely dose
Minocycline 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01693523
NCT01693523Phase 2Completed
CompareCT.gov

A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden for Pancreatic Cancer Patients

M.D. Anderson Cancer Center·interventional·Posted Sep 26, 2012·Updated Mar 9, 2020

In Brief

A Phase 2 clinical trial evaluating Minocycline, Placebo, and 1 other intervention for Pancreatic Cancer. Completed, enrolled 80 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if minocycline can reduce the side effects of chemotherapy in patients with pancreatic cancer. In this study, minocycline will be compared to a placebo. Minocycline is an antibiotic that may help to reduce side effects of chemotherapy. A placebo is not a drug. It looks like the study drug, but it is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 26, 2012
Enrollment StartJan 28, 2013
Primary CompletionSep 19, 2018
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 13.8 years ago

Interventions

Minocyclinedrug

100 mg by mouth two times a day (200 mg/day).

Placeboother

Matching placebo capsules by mouth twice a day.

Questionnairesbehavioral

Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.